Publicaciones en colaboración con investigadores/as de Hospital Universitario de Valme (18)

2022

  1. Orthohepevirus C infection as an emerging cause of acute hepatitis in Spain: First report in Europe

    Journal of Hepatology, Vol. 77, Núm. 2, pp. 326-331

2021

  1. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

    Journal of Hepatology, Vol. 74, Núm. 4, pp. 801-810

  2. Limited Value of Single Sampling for IgM Antibody Determination as a Diagnostic Approach for Acute Hepatitis E Virus Infection

    Microbiology Spectrum, Vol. 9, Núm. 1, pp. 1-5

  3. Vaccinated patients admitted in icu with severe pneumonia due to sars-cov-2: A multicenter pilot study

    Journal of Personalized Medicine, Vol. 11, Núm. 11

2020

  1. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 71, Núm. 9, pp. 2354-2362

  2. Sample pooling for SARS-CoV-2 RT-PCR screening

    Clinical Microbiology and Infection, Vol. 26, Núm. 12, pp. 1687.e1-1687.e5

  3. Towards the elimination of hepatitis C: Implementation of reflex testing in Andalusia

    Revista Espanola de Enfermedades Digestivas, Vol. 112, Núm. 7, pp. 515-519

2019

  1. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals

    AIDS, Vol. 33, Núm. 7, pp. 1167-1174

  2. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world

    Journal of Hepatology, Vol. 71, Núm. 5, pp. 876-888

  3. The simplification of the diagnosis process of chronic hepatitis C is cost-effective strategy

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 10, pp. 634-641

2018

  1. Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis

    PLoS ONE, Vol. 13, Núm. 7

2017

  1. Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals

    Diagnostic Microbiology and Infectious Disease, Vol. 89, Núm. 1, pp. 29-34

  2. Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 5, pp. 853-861

  3. Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the GEHEP 005 study)

    Journal of Viral Hepatitis, Vol. 24, Núm. 9, pp. 725-732

  4. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection

    Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8

2014

  1. Predictors of early mortality in very elderly patients with bacteremia: A prospective multicenter cohort

    International Journal of Infectious Diseases, Vol. 26, pp. 83-87

2012

  1. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: A propensity score-based analysis

    Antimicrobial Agents and Chemotherapy, Vol. 56, Núm. 1, pp. 472-478

2010

  1. Designing a clinical microbiology laboratory

    Enfermedades Infecciosas y Microbiologia Clinica